Last reviewed · How we verify
NCT07194421
In-Use Tolerance & Efficacy Study Under Dermatological Control of Sunscreen in Adults With Atopic Dermatitis Skin
trial testing Sunscreen RV4620A RP2552 in Atopic Dermatitis (AD) in 42 participants. Completed in 9 February 2024.
9 February 2024
Quick facts
| Lead sponsor | Pierre Fabre Dermo Cosmetique |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 42 |
| Start date | 10 October 2023 |
| Primary completion | 9 February 2024 |
| Estimated completion | 9 February 2024 |
| Sites | 1 location across Mauritius |
Drugs / interventions tested
- Sunscreen RV4620A RP2552
Conditions studied
- Atopic Dermatitis (AD) — all drugs for Atopic Dermatitis (AD) →
- SCORAD Index(15-25) — all drugs for SCORAD Index(15-25) →
Sponsor
Pierre Fabre Dermo Cosmetique — full company profile →
Who can join
Adults 18 to 45, any sex, with Atopic Dermatitis (AD) or SCORAD Index(15-25). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates a broad-spectrum SPF50+ sunscreen on 42 adults with Atopic Dermatitis, measuring skin tolerance and barrier function. The study includes several visits as follow : * Visit 1: Inclusion (Day 1) * Visit 2: Intermediate Visit (Day 8) * Visit 3: End of Study (Day 22)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07194421
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sunscreen RV4620A RP2552
Trials testing the same drug.
- NCT07194408 — In-Use Tolerance Study Under Dermatological and Pediatric Controls of Sunscreen in Children With Atopic Dermatitis · completed
Other recruiting trials for Atopic Dermatitis (AD)
Currently open trials in the same condition.
- NCT07146971 — Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis · Phase 1 · recruiting
- NCT07235384 — A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participan · Phase 1 · recruiting
- NCT07259343 — Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization · NA · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
- NCT07105488 — A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
Other Pierre Fabre Dermo Cosmetique trials
Trials by the same sponsor.
- NCT07014007 — Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks · NA · not yet recruiting
- NCT07166484 — Assessment of the Effect of the Product RV2666C Formula LA2984 Compared to an Untreated Area With an Epidermally Ablated · not yet recruiting
- NCT06983561 — Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regard · recruiting
- NCT07341659 — Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subject · NA · active not recruiting
- NCT06800755 — Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07194421 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pierre Fabre Dermo Cosmetique
- Last refreshed: 26 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07194421.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing